Pituitary dwarfism 1

Also Known As:

Growth hormone deficiency, isolated, autosomal recessive; IGHD1A; Isolated Growth Hormone Deficiency, Type IA; Isolated growth hormone deficiency, type 1b; Nanism due to growth hormone isolated deficiency; Pituitary Dwarfism I; Sexual ateleiotic dwarfism

Networked: 8 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Pituitary Dwarfism

Experts

1.	Chang, Guo-ying: 1 article (12/2010)
2.	Dong, Zhi-ya: 1 article (12/2010)
3.	Wang, De-fen: 1 article (12/2010)
4.	Wang, Wei: 1 article (12/2010)
5.	De Luca, F: 1 article (04/2001)
6.	Ghizzoni, L: 1 article (04/2001)
7.	Lombardo, F: 1 article (04/2001)
8.	Messina, M F: 1 article (04/2001)
9.	Valenzise, M: 1 article (04/2001)
10.	Wasniewska, M: 1 article (04/2001)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pituitary dwarfism 1:

1.	Human Growth Hormone (Saizen)FDA LinkGeneric 12/01/2010 - "To elucidate the curative and adverse effect of recombinant human growth hormone (rhGH) in 2 patients with isolated-growth hormone deficiency type IA (IGHDIA), to track sexual development and pregnancy, and reassess the quality of life in the adulthood. " 11/01/1994 - "Isolated growth hormone deficiency type IA associated with a 45-kilobase gene deletion within the human growth hormone gene cluster in an Italian family."
2.	Growth Hormone (Somatotropin)IBA 11/01/1989 - "Two brothers with familial isolated growth hormone deficiency type IA homozygous for the same 6.7 kb deletion on chromosome 17 including the growth hormone gene were intermittently treated with various forms of hGH for more than 7 years. " 11/01/1989 - "Discordant immune and growth response to pituitary and biosynthetic growth hormone in siblings with isolated growth hormone deficiency type IA." 05/01/1971 - "Sexual ateleiotic dwarfism associated with normal plasma growth hormone levels."
3.	Insulin-Like Growth Factor I (IGF-1)IBA 04/01/2001 - "In this paper we report the FH outcome of two girls with IGHD1A who were treated either with GH only (first patient) or with GH during the first 8 years and successively with IGF-I (second patient). " 11/01/1993 - "Treatment of isolated growth hormone deficiency type IA due to GH-I gene deletion with recombinant human insulin-like growth factor I." 04/01/2001 - "We conclude that IGHD1A could have a very heterogeneous phenotypic expression in terms of FH and that IGF-I therapy, even though initiated some years before puberty onset and prolonged for more than 5 years, may not be able to ensure the normalization of height prognosis and the achievement of an FH close to TH." 04/01/2001 - "Surprisingly, FH was severely subnormal and very far from TH in the patient who underwent IGF-I therapy for >5 years: an auxological outcome similar to the one recently reported in the only two cases in the literature of patients with IGHD1A who have been treated with IGF-I until near FH achievement. "
4.	DNA (Deoxyribonucleic Acid)IBA 04/01/1992 - "At least three different sizes of GH-1 gene deletions (approximately 6.7, 7.0 and 7.6 kilobases) have been detected by Southern blot analysis of DNA from individuals with familial isolated GH deficiency type IA (IGHD1A). " 06/01/1990 - "To facilitate detection of cases of IGHD1A, we have developed a rapid method that uses polymerase chain reaction amplification of small amounts of genomic DNA, digestion with a single restriction endonuclease, and visualization of DNA fragments after gel electrophoresis. "
5.	DNA Restriction Enzymes (Restriction Endonuclease)IBA 06/01/1990 - "To facilitate detection of cases of IGHD1A, we have developed a rapid method that uses polymerase chain reaction amplification of small amounts of genomic DNA, digestion with a single restriction endonuclease, and visualization of DNA fragments after gel electrophoresis. "

Therapies and Procedures

Therapeutics

11/01/1989 - "These findings demonstrate that therapy with biosynthetic methionyl hGH may provide an effective form of treatment for subjects with isolated growth hormone deficiency type IA who do not grow in response to native hGH, and imply that biosynthetic methionyl hGH may be less antigenic than pituitary derived hGH."
04/01/2001 - "We conclude that IGHD1A could have a very heterogeneous phenotypic expression in terms of FH and that IGF-I therapy, even though initiated some years before puberty onset and prolonged for more than 5 years, may not be able to ensure the normalization of height prognosis and the achievement of an FH close to TH."
04/01/2001 - "Surprisingly, FH was severely subnormal and very far from TH in the patient who underwent IGF-I therapy for >5 years: an auxological outcome similar to the one recently reported in the only two cases in the literature of patients with IGHD1A who have been treated with IGF-I until near FH achievement. "